Results 191 to 200 of about 6,081 (225)
Some of the next articles are maybe not open access.
Randomized Clinical Trials with Levosimendan
The American Journal of Cardiology, 2005There are important unmet needs in the treatment of acute heart failure syndromes (AHFS). The unique dual mechanism of action of levosimendan suggests that this new agent may help fill some of these unmet needs. A review of randomized, controlled clinical trials with levosimendan demonstrated that it is well tolerated, and its use results in ...
Damien Barraud +2 more
openaire +3 more sources
A promising new inotrope: levosimendan
Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology, 2010Intravenous positive inotropic agents are commonly used to treat the patients with acute decompensated heart failure due to left ventricular systolic dysfunction. Although these agents seem to be beneficial for improving symptoms of heart failure in the short-term; it has been reported that they are associated with increased mortality and morbidity ...
Dursun Duman, Hakan Fotbolcu
openaire +3 more sources
Der Anaesthesist, 2004
Levosimendan is a recently developed drug which is not yet approved for clinical routine use in Germany. The clinical use is limited to a few selected cases and it has been used as a salvage therapy in patients with severe heart insufficiency. As a potent inodilator it has been given to patients with severe heart failure, when all other therapeutic ...
Claudia Spies +8 more
openaire +3 more sources
Levosimendan is a recently developed drug which is not yet approved for clinical routine use in Germany. The clinical use is limited to a few selected cases and it has been used as a salvage therapy in patients with severe heart insufficiency. As a potent inodilator it has been given to patients with severe heart failure, when all other therapeutic ...
Claudia Spies +8 more
openaire +3 more sources
Levosimendan Following Cardiac Surgery
Heart, Lung and Circulation, 2019A best evidence topic was written to address if perioperative levosimendan improves mortality following cardiac surgery. Fourteen papers represented the best available evidence. An older meta-analysis summarising 11 of these trials concluded that there were fewer deaths in the levosimendan group compared to the control group (OR 0.41, p
Daniel Florisson +4 more
openaire +3 more sources
Tricuspid valve replacement and levosimendan
General Thoracic and Cardiovascular Surgery, 2008Isolated tricuspid valve replacement, which is not a common operation, is associated with poor short and long-term results, and the postoperative morbidity and mortality rates are high. The main reason for these adverse effects is the acute manifestation of chronic right heart failure.
Ali Ihsan Parlar +4 more
openaire +3 more sources
Levosimendan: Calcium Sensitizer and Inodilator
Anesthesiology Clinics, 2010Levosimendan is a unique therapeutic agent that decreases mortality in acute episodes of decompensated heart failure by increasing myocardial contractility without increasing oxygen consumption or ATP demands, decreasing preload, or decreasing afterload. The mechanism for each accomplishment is novel.
Aaron M. Fields, Daun Johnson Milligan
openaire +3 more sources
Impact of levosimendan on platelet function
Thrombosis Research, 2017Levosimendan has been developed for treatment of severe heart failure. The favorable hemodynamic effect of levosimendan is related to its unique dual mechanism of action - increase of the contractile force of the myocardium caused by enhanced sensitivity of myofilaments to calcium combined with vasodilatation caused by the opening of adenosine ...
Joanna Sikora +8 more
openaire +3 more sources
The role of Levosimendan in cardiopulmonary resuscitation
European Journal of Pharmacology, 2014Although initial resuscitation from cardiac arrest (CA) has increased over the past years, long term survival rates remain dismal. Epinephrine is the vasopressor of choice in the treatment of CA. However, its efficacy has been questioned, as it has no apparent benefits for long-term survival or favorable neurologic outcome. Levosimendan is an inodilator
Giolanda Varvarousi +4 more
openaire +2 more sources
Vasodilating Mechanisms of Levosimendan [PDF]
Cardiovascular Drugs and Therapy, 2003 Nick Sperelakis, Hisashi Yokoshiki
openaire +2 more sources
DMW - Deutsche Medizinische Wochenschrift, 2005
G, Michels, S, Herzig, U C, Hoppe
openaire +2 more sources
G, Michels, S, Herzig, U C, Hoppe
openaire +2 more sources